MB
Maryellen Babcock
View Maryellen's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
N/A
Jan 2022 - Present · 2 years and 11 months
N/A
Mar 2019 - Jul 2019 · 4 months
Keryx Biopharmaceuticals
N/A
May 2018 - Mar 2019 · 10 months
Company Details
51-200 Employees
We are a commercial-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. We have successfully developed mavorixafor, receiving FDA approval for XOLREMDI™ (mavorixafor) in its first indication, and are currently executing our US launch. We are also advancing mavorixafor for additional rare disease patient populations, and expect to initiate a pivotal, global Phase 3 clinical trial in people with certain chronic neutropenic disorders. With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.
Year Founded
2014
Social Media
Linkedin
Industry
Biotechnology Research
HQ Location
61 N Beacon St Boston, Massachusetts 02134, US
Keywords
Rare disease and primary immunodeficiencies
Discover More About Cleveland Clinic

Find verified contacts of Maryellen Babcock in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.